跳至主要内容
临床试验/ACTRN12612000535875
ACTRN12612000535875已完成1 期

In paediatric patients with high risk brain tumours, is it safe and feasible to infuse autologous Peripheral Blood Stem Cells transduced with a mutant MGMT Gene?

The Sydney Children's Hospital Network0 个研究点目标入组 12 人开始时间: 2012年5月21日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment

入排标准

年龄范围
1 Years 至 21 Years(—)
性别
All

入选标准

  • 1. Patient diagnosed with one of the following:
  • a) High grade glioma which has progessed or recurred following standard therapy
  • b) Medulloblastoma which has recurred following conventional therapy
  • c) Ependymoma which has recurred following maximal safe surgical resection and radiotherapy, and where maximal safe re-section and re-irradiation has been undertaken or considered not appropriate
  • d) Atypical teratoid/rhabdoid tumour which has recurred
  • e) Low grade glioma which has recurred
  • f) Brainstem glioma of diffuse pontine type
  • 2. Life expectancy greater than or equal to 8 weeks
  • 3. No severe uncontrolled infection
  • 4. Performance status :
  • a) Karnofsky score > or equal to 50% (patient over 10 years old) OR
  • b) Lansky score > or equal to 50% (patient under/equal 10 years old)
  • 5. Patient has adequate bone marrow function
  • 6. Signed Informed Consent

排除标准

  • 1. Uncontrolled infection
  • 2. Malignant infiltration of the bone marrow or any other site outside the central nervous system

研究者

发起方
The Sydney Children's Hospital Network

相似试验